As 2024 concludes, the year has left us with significant milestones and breakthroughs in oncology. Oncology Frontier invited Dr. Yongmei Yin from Jiangsu Cancer Hospital to summarize the year's advancements in HER2-positive breast cancer research, highlighting the clinical transformations brought by innovative therapies.

Editor’s Note: With the discovery of lung cancer driver genes and the rapid development of drug research, targeted therapy for advanced non-small cell lung cancer (NSCLC) has made significant progress,…

Pancreatic cancer (PC) stands as one of the most lethal cancers globally, ranking 12th in prevalence and sixth in cancer-related deaths. Its aggressive nature and often late diagnosis contribute to a dismal 5-year survival rate of merely 12%. While surgical resection offers the only potential cure, most patients are diagnosed at advanced stages, rendering surgery ineffective. Currently, effective and cost-efficient screening tools for the general population are lacking, and recommended screening strategies, like cross-sectional imaging and endoscopic ultrasonography, are limited to high-risk individuals.

At the end of 2024, the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the "New Little Red Book") was officially released during the 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee. This updated edition provides fresh guidance for clinical breast cancer practices.

Editor’s Note: The 2024 Academic Conference on Precision Diagnosis and Treatment of Lung Cancer recently featured a presentation by Dr. Yan Huang from the Sun Yat-sen University Cancer Center, titled…

In recent years, as research has deepened, the exploration of gastric cancer's molecular mechanisms has gradually shifted from histological classification to molecular classification. Different biomarkers have profoundly influenced the treatment landscape of advanced gastric cancer in first-line and subsequent therapies. At the close of this year, Oncology Frontier  is honored to invite Dr. Ai Li Suo from The First Affiliated Hospital of Xi’an Jiaotong University to review and summarize the latest advancements and hot topics in targeted therapy for advanced gastric cancer in 2024. Reflecting on the past and looking toward the future, Professor Suo provides insights and recommendations for the development of advanced gastric cancer treatment.

The "Northern Breast Cancer Salon Annual Progress Review" was held from January 3–5, 2025, in Beijing. The conference comprehensively reviewed the latest advances in breast cancer diagnosis, treatment, and research over the past year, delving into the latest findings for various breast cancer subtypes and their impact on clinical practice. The conference also focused on discussions regarding updates to the CSCO BC guidelines, providing scientific guidance for clinical practice in breast cancer. At the event, Oncology Frontier invited Dr. Kun Wang from Guangdong Provincial People's Hospital to review the past year’s advancements in the field of early triple-negative breast cancer (TNBC) treatment.

Editor’s Note: With the continuous advancement of medical research, the field of treatment for advanced triple-negative breast cancer (TNBC) is experiencing unprecedented transformation. During the recently held "Northern Breast Cancer…

With the ongoing advancements in breast cancer research, BRCA gene mutations, as a significant genetic risk factor for breast cancer, have attracted increasing attention. In this article, Dr. Songqing Ye from Fujian Provincial Hospital will provide a detailed discussion on the prognosis and treatment advances for BRCA-mutated breast cancer patients, covering the association between BRCA genes and breast cancer, the impact of genetic mutations on prognosis, treatment options, and a comprehensive review of the latest clinical research findings.

Editor's Note: At the end of 2024, the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the "New Little Red Book") was…